Veraxa Biotech is trading 6.5% up in pre-market at $1.48, versus the September 23 close of $1.39, amid broader biotech momentum on September 24, 2026.
- XBI was up 2.61% pre-market, supported by positive clinical and regulatory updates from other biotechnology companies.
- No new company-specific announcement was identified overnight.
- Recent oncology-pipeline coverage and the CFO appointment are older developments, not fresh catalysts.